848695-25-0 | BIIB021

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$33.00	$23.00
5mg	95%	in stock	$65.00	$45.00
10mg	95%	in stock	$114.00	$80.00
100mg	95%	in stock	$194.00	$136.00
250mg	95%	in stock	$362.00	$253.00

Description

• Catalog Number: AD93820
• Chemical Name: BIIB021
• CAS Number: 848695-25-0
• Molecular Formula: C14H15ClN6O
• Molecular Weight: 318.7615
• MDL Number: MFCD15528939
• SMILES: COc1c(C)cnc(c1C)Cn1cnc2c1nc(N)nc2Cl

Computed Properties

• Complexity: 388
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 1.9

Literature

• Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.

  Immunopharmacology and immunotoxicology 20160101

• Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

  Bioorganic & medicinal chemistry letters 20140101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• EC144 is a potent inhibitor of the heat shock protein 90.

  Journal of medicinal chemistry 20120913

• In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• ATPases as drug targets: insights from heat shock proteins 70 and 90.

  Journal of medicinal chemistry 20101028

• BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.

  International journal of cancer 20100301

• BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.

  International journal of cancer 20100301

• An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20100201

• Heat shock protein 90: inhibitors in clinical trials.

  Journal of medicinal chemistry 20100114

• Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090815

• BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

  Molecular cancer therapeutics 20090401

• Discovery and development of heat shock protein 90 inhibitors.

  Bioorganic & medicinal chemistry 20090315

• Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

  Journal of medicinal chemistry 20070614